Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The SLC25A22 mRNA 3′-untranslated region (3′-UTR) is a critical regulatory segment of the messenger RNA that encodes the mitochondrial glutamate carrier 1 (GC1). This region serves as a primary site for post-transcriptional control, where it interacts with microRNAs (miRNAs) and RNA-binding proteins to modulate the stability and translation of the SLC25A22 transcript (1.2.2, 1.4.3). A key regulator of this 3′-UTR is miR-184, which binds to specific recognition elements to induce mRNA degradation or repress protein synthesis, thereby influencing cellular processes such as insulin secretion and tumor cell metabolism (1.2.2, 1.4.1). SLC25A22 itself is essential for transporting glutamate into the mitochondrial matrix, a process vital for the tricarboxylic acid (TCA) cycle and amino acid biosynthesis (1.3.1, 1.3.5). In oncology, the SLC25A22 mRNA 3′-UTR is an emerging therapeutic target; for instance, using miR-184 mimics to target this region has been shown to reduce radioresistance and aggressiveness in glioblastoma (1.4.1). Conversely, mutations in the SLC25A22 gene are linked to severe neonatal epileptic encephalopathies, highlighting the importance of precise regulation of this carrier for normal neurological function (1.1.1, 1.3.2).
MicroRNA-mediated gene silencing, RNA interference (RNAi), and translational inhibition leading to reduced protein expression.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 25 member 22 mRNA 3′-untranslated region (SLC25A22 mRNA 3′-UTR) (SLC25A22 mRNA 3′-UTR).